DataSheet_1_EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells.pdf
Enhancer of Zeste Homolog 2 (EZH2) inhibitors (EZH2i) are approved to treat certain cancer types. Previous studies have suggested the potential to combine EZH2i with immune checkpoint blockade targeting coinhibitory receptors like PD-(L)1 and CTLA-4, but whether it can also enhance the activity of agents targeting costimulatory receptors is not known. Here, we explore the combination between EZH2i and an agonist antibody targeting the T cell costimulatory receptor 4-1BB (α4-1BB). Our data show that EZH2i compromise the efficacy of α4-1BB in both CT26 colon carcinoma and in an in vivo protein immunization model. We link this to reduced effector survival and increased BIM expression in CD8+ T cells upon EZH2i treatment. These data support the requirement of EZH2 function in 4-1BB-mediated CD8+ T cell expansion and effector programming and emphasize the consideration that must be given when combining such antitumoral therapies.
History
References
- https://doi.org//10.1186/s13045-020-00937-8
- https://doi.org//10.2217/fon-2020-1244
- https://doi.org//10.1021/acs.jmedchem.7b01375
- https://doi.org//10.1158/0008-5472.CAN-20-2147
- https://doi.org//10.1038/nm.4036
- https://doi.org//10.1038/nature09784
- https://doi.org//10.1038/s43018-021-00185-w
- https://doi.org//10.1158/1078-0432.CCR-19-1351
- https://doi.org//10.1172/JCI99760
- https://doi.org//10.1016/j.celrep.2017.07.007
- https://doi.org//10.1016/j.celrep.2018.05.050
- https://doi.org//10.1158/1078-0432.CCR-19-1868
- https://doi.org//10.1182/blood-2011-06-364422
- https://doi.org//10.1182/blood-2013-05-505180
- https://doi.org//10.1016/j.immuni.2017.03.012
- https://doi.org//10.1038/ni.3688
- https://doi.org//10.1038/s41467-017-02187-8
- https://doi.org//10.1158/2326-6066.CIR-18-0054
- https://doi.org//10.4049/jimmunol.169.9.4882
- https://doi.org//10.1038/nm0697-682
- https://doi.org//10.1084/jem.20121190
- https://doi.org//10.1182/blood-2017-06-741041
- https://doi.org//10.1158/2326-6066.CIR-16-0364
- https://doi.org//10.1016/j.celrep.2020.108115
- https://doi.org//10.3389/fimmu.2017.01696
- https://doi.org//10.1186/2051-1426-1-14
- https://doi.org//10.1016/j.immuni.2015.01.007
- https://doi.org//10.1016/j.immuni.2007.07.010
- https://doi.org//10.1084/jem.20130392
- https://doi.org//10.1126/science.abb9847
- https://doi.org//10.1038/ni.3313
- https://doi.org//10.4049/jimmunol.1100102
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity
